Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$119.10 USD

119.10
722,614

+0.60 (0.51%)

Updated Sep 4, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

by Zacks Equity Research

Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.

Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales

by Zacks Equity Research

Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.

Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View

by Zacks Equity Research

Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.

Has Novartis (NVS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVS) Outperforming Other Medical Stocks This Year?

Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat

by Zacks Equity Research

Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA

by Kinjel Shah

Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) release Q3 results. FDA approves Glaxo's (GSK) Zejula and AstraZeneca's Farxiga for more patients. CHMP gives nod to several drugs

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.

Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.

Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More

by Zacks Equity Research

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.

Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y

by Zacks Equity Research

Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.

Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

by Zacks Equity Research

Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

Roche Posts Solid Sales for First 9 Months of '19, Ups View

by Zacks Equity Research

Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

Roche Announces Positive Late-Stage Data on Rituxan in PV

by Zacks Equity Research

Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.

Kinjel Shah headshot

Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

by Kinjel Shah

FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

Ekta Bagri headshot

Wet AMD Space in Focus: New Drug Approvals & Key Advancements

by Ekta Bagri

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval

by Zacks Equity Research

Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.

Is Novartis (NVS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVS) Outperforming Other Medical Stocks This Year?

Biogen Strengthens MS & SMA Portfolio as Competition Lurks

by Zacks Equity Research

Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.

AstraZeneca's Fasenra Gets FDA Nod for Self-Administration

by Zacks Equity Research

The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study

Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx

by Zacks Equity Research

The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY

by Kinjel Shah

J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.

Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

by Zacks Equity Research

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.